- AU$678.36m
- AU$993.71m
- AU$469.70m
- 71
- 48
- 77
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.33 | ||
| PEG Ratio (f) | 0.29 | ||
| EPS Growth (f) | 441.58% | ||
| Dividend Yield (f) | 3.01% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.25 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.04 | ||
| Price to Sales | 1.44 | ||
| EV to EBITDA | 86.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.37% | ||
| Return on Equity | -17.99% | ||
| Operating Margin | -7.53% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 275.57 | 350.7 | 360.93 | 440.79 | 469.7 | 576.06 | 662.14 | 15.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -24.32 | +18.58 | -32.51 | -12.71 | n/a | n/a | +38.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Integral Diagnostics Limited is an Australia-based provider of medical imaging services across Australia and New Zealand. The principal activity of the Company is the provision of diagnostic imaging services. It operates brands in four Australian States: Lake Imaging in Victoria, the X-Ray Group in VIC/NSW, South Coast Radiology, Peloton Radiology and Imaging Queensland in Queensland and Apex Radiology in Western Australia. It also operates in New Zealand through the Astra Radiology, SRG Radiology, Horizon Radiology and Trinity MRI brands. Lake Imaging offers a private radiology service to patients throughout Central and Western Victoria. South Coast Radiology provides medical imaging services and patient care to the Gold Coast and Tweed Heads communities. Imaging Queensland is a provider of advanced diagnostic imaging services and radiology education across Queensland. Apex Radiology provides diagnostic imaging services for patients in rural and regional communities.
Directors
- Helen Kurincic NEC
- Ian Kadish CEO
- Anne Lockwood CFO
- Paul Mccrow COO
- Nazar Bokani EDR
- Jacqueline Milne EDR
- Lisa Sorger OTH
- Kirsty Lally SEC
- John Atkin NID
- Raelene Murphy NID
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- April 29th, 2008
- Public Since
- October 21st, 2015
- No. of Shareholders
- 5,259
- No. of Employees
- 1,977
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 233,915,810
- Address
- Suite 9.02, Level 9, 45 William Street, MELBOURNE, 3051
- Web
- https://www.integraldiagnostics.com.au/
- Phone
- +61 353390704
- Auditors
- PricewaterhouseCoopers
Upcoming Events for IDX
Similar to IDX
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Capitol Health
Australian Stock Exchange - SEATS
FAQ
What is the Integral Diagnostics share price?
As of Today at 20:20 UTC, shares in Integral Diagnostics are trading at AU$2.90. This share price information is delayed by 15 minutes.
How has the Integral Diagnostics share price performed this year?
Shares in Integral Diagnostics last closed at AU$2.90 and the price had moved by +55.08% over the past 365 days. In terms of relative price strength the Integral Diagnostics share price has outperformed the ASX All Ordinaries Index by +32.29% over the past year.
What are the analyst and broker recommendations for Integral Diagnostics?
The overall consensus recommendation for Integral Diagnostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Integral Diagnostics dividend yield?
The Integral Diagnostics dividend yield is 2% based on the trailing twelve month period.
Does Integral Diagnostics pay a dividend?
Last year, Integral Diagnostics paid a total dividend of AU$0.06, and it currently has a trailing dividend yield of 2%. We do not have any data on when Integral Diagnostics is to next pay dividends.
When does Integral Diagnostics next pay dividends?
We do not have data on when Integral Diagnostics is to next pay dividends. The historic dividend yield on Integral Diagnostics shares is currently 2%.
How do I buy Integral Diagnostics shares?
To buy shares in Integral Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Integral Diagnostics?
As of the previous close price of AU$2.90, shares in Integral Diagnostics had a market capitalisation of AU$678.36m.
Where are Integral Diagnostics shares listed?
Here are the trading details for Integral Diagnostics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IDX
What kind of share is Integral Diagnostics?
Based on an overall assessment of its quality, value and momentum Integral Diagnostics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Integral Diagnostics share price forecast for 2024?
The analyst consensus target price for shares in Integral Diagnostics is AU$3.21. That is 10.76% above the last closing price of AU$2.90.
Analysts covering Integral Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of AU$0.11 for the next financial year.
Find out moreWhat is the trend in the Integral Diagnostics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integral Diagnostics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +11.69%.
As of the last closing price of AU$2.90, shares in Integral Diagnostics were trading +11.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Integral Diagnostics PE Ratio?
The Integral Diagnostics PE ratio based on its reported earnings over the past 12 months is 23.33. The shares last closed at AU$2.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Integral Diagnostics?
Integral Diagnostics' management team is headed by:
- Helen Kurincic - NEC
- Ian Kadish - CEO
- Anne Lockwood - CFO
- Paul Mccrow - COO
- Nazar Bokani - EDR
- Jacqueline Milne - EDR
- Lisa Sorger - OTH
- Kirsty Lally - SEC
- John Atkin - NID
- Raelene Murphy - NID